Navigation Links
SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing
Date:4/24/2012

of dystrophin, the protein missing in the muscle fibers of patients with DMD.

In May 2011, an MDA-supported study showed that daily treatment with SMT C1100 dramatically reduced symptoms in dystrophin-deficient mice with a DMD-like disease. The mice showed reduced muscle abnormalities, increased overall strength and improved ability to resist exercise-related fatigue.

An earlier version of the drug, tested by California-based BioMarin Pharmaceutical, was found safe and well-tolerated in healthy human volunteers, but it failed to reach blood levels considered adequate for therapy.

The reformulated Summit PLC version of the drug is designed to reach adequate blood levels in humans following oral administration.

To learn more, read the Quest News Online article DMD Drug SMT C1100 Moves to Human Testing.

About DMD

DMD is a degenerative muscle disease — affecting boys almost exclusively — that involves progressive degeneration of voluntary and cardiac muscles, with resulting weakness and heart abnormalities. The disease manifests in early childhood, causing delayed motor milestones and, in some cases, cognitive, behavioral or language deficits. Loss of the ability to walk occurs in most children with DMD between the ages of 10 and 12 years; weakened cardiac and respiratory muscles severely limit life span.

The disease is caused by any number of mutations in the X-chromosome gene that carries instructions for the muscle protein dystrophin. Without dystrophin, muscle fibers are abnormally fragile and break down under the stress of contractions.

Corticosteroid medications, such as prednisone and its chemical cousin prednisolone, slow disease progressi
'/>"/>

SOURCE Muscular Dystrophy Association
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Halo Therapeutics HT-100 Receives FDAs Orphan Designation for Duchenne Muscular Dystrophy
2. MDA Awards $750,000 to Help Summit Test New Drug Formulation in Phase 1 Clinical Trial of Potential Treatment for Duchenne Muscular Dystrophy
3. MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy
4. PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
5. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
6. Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy
7. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
8. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
9. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
10. PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
11. MDA Awards $1 Million to Tivorsan Pharmaceuticals for Accelerating Pivotal Pre-Clinical Work on TVN-102 as a Potential Muscular Dystrophy Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... mayo de 2013 La junta directiva ... incluyen OMNIlife science®, Inc., Enztec, Ltd. y Praxim, SA, ... junta. Guy Mayer, un ejecutivo ortopédico experimentado, será vicepresidente ... Johnson , un experto refutado en dispositivos ... de unirse a OSI como presidente de la ...
(Date:5/21/2013)... PHILADELPHIA , May 21, 2013 ... and impressive new product developments at the Special Libraries Association ... years of unerring focus on product literature databases and workflow ... mark the occasion," said founding director Nigel Johnson ... developments of benefit to our clients and what better forum ...
(Date:5/21/2013)... BURLINGTON, Mass. , May 21, 2013 ... leading research and advisory firms for pharmaceutical ... of an emerging agent on key efficacy ... disease progression, has the most influence over ... for advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast ...
Breaking Medicine Technology:Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2
... July 25, 2011 Prasco Laboratories, the Authorized Generics company, ... Shionogi Inc . Under the terms of the agreement, ... USP 250 mg, the Authorized Generic version of Ponstel ... in the U.S. under the Prasco label. "With ...
... 25, 2011 Cornerstone Pharmaceuticals, Inc., ( www.cornerstonepharma.com ... cancer metabolism-based therapeutics, today announced the publication of ... Medicine ( http://tinyurl.com/3ugohzd ) describing the selective ... novel lipoate derivative compounds.  Specifically, the publication illuminates ...
Cached Medicine Technology:Prasco® Announces Authorized Generic Agreement with Shionogi Inc. 2Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicine's Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds 2Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicine's Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds 3Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicine's Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds 4
(Date:5/21/2013)... Boca Raton, Fla. (PRWEB) May 21, 2013 ... TV program distributed on cable networks and cable channels ... of new episodes on its YouTube channel. The producers ... profiles of companies in the shipping industry, the manufacturing ... program highlights pioneering medical facilities and medical practitioners in ...
(Date:5/21/2013)... May 21, 2013 MedMar Healing Center ... to benefit Second Harvest Food Bank. Twenty-eight businesses, including MedMar ... in the food drive. The goal is to raise food ... economic problems facing their families in recent years. , ... and help those in need,” explains Douglas Chloupek of MedMar ...
(Date:5/21/2013)... genetic features of pulmonary fibrosis by physicians and scientists ... lead to improved treatment of this deadly lung disease, ... . , The study found that a particular genetic ... fibrosis, a chronic progressive disease with a median survival ... researchers may want to consider including genetic testing in ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... robot lawsuit is nearing its conclusion in Washington ... Bloomberg.com, during closing statements yesterday, an attorney for the ... the company wanted to tie sales and services for ... the training to keep control of surgeons, to keep ...
(Date:5/21/2013)... Two executives from human resources and pharmacy ... strategies can be most effective to better manage costly ... who are taking them, in an upcoming May 30 ... Manage Specialty Drugs to Reduce Costs and Ensure Quality ... driver for rising prescription drug costs, which are an ...
Breaking Medicine News(10 mins):Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2
... Paralleling the nation,s efforts to find ways to expand ... care, Concierge Choice Physicians (CCP) announced in ... physicians care for more than 250,000 patients in 12 states - ... Pioneering the concept of hybrid concierge medicine, CCP offers primary care ...
... EAST HAMPTON, N.Y., July 8 The Max Cure Foundation ... cancer causes -- announced today its first charity benefit, the ... day, to take place on Saturday, August 22, from 2:00 ... grounds of the East Hampton Indoor Tennis Club, 175 Daniels ...
... 8 Insulet Corporation (Nasdaq: PODD ), ... that the Company is introducing an environmentally friendly disposal ... Eco-Pod program will reduce the impact of used Pods ... landfills. It is the industry,s first program for ...
... the most famous hotels in Coconut Grove, Florida is now offering ... , In the spirit of game shows of yesterday and today, ... Deal special. It,s simple...call the hotel, mention the Let,s Make a ... suites...the hotel may counter with a Deal or No Deal offer, ...
... July 8 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... quarter ended June 30, 2009, on Thursday, August 6, ... a conference call and webcast on Thursday, August 6, ... Company,s second quarter results and current corporate developments. The dial-in number ...
... July 8 You,ve just waited through the longest two minutes ... to be positive. After catching your breath, you realize the only ... same again. That,s because you,ve just learned you,re pregnant! This discovery ... mind, and you know you need fast answers. That,s when you ...
Cached Medicine News:Health News:Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide 2Health News:Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 2Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 4Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 5Health News:Insulet Establishes Eco-Friendly Disposal Program for the OmniPod(R) Insulin Management System 2Health News:A Unique Rhythm In The Heart Of Coconut Grove, Florida 2Health News:Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 2Health News:A Bundle of Joy Brings a Bundle of Questions - Life123.com Delivers the Answers! 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: